The company is making a high-risk, high-reward bet with the purchase of Gyroscope.
Amid cautionary tales of other highly valued unpartnered assets, efgartigimod approaches its US date with destiny.
A strong performance from a handful of large drug developers could not rescue the sector from a weak three months on the stock market.
Despite several recent late-stage failures, there is still a lot going on in the ALS pipeline.
A hit and a miss with pegcetacoplan in late-stage trials leaves Apellis with shrinking prospects.
Late-stage data are expected for Apellis; Ionis and Biogen tackle ALS; and Mirati awaits combination results.
Pivotal development of GEM103 is set to proceed, but the phase 2 result is a cautionary tale – not only for Gemini.